Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021
Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, s...
Gespeichert in:
Veröffentlicht in: | Internal medicine journal 2021-11, Vol.51 (S7), p.18-36 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 36 |
---|---|
container_issue | S7 |
container_start_page | 18 |
container_title | Internal medicine journal |
container_volume | 51 |
creator | Khanina, Anna Tio, Shio Yen Ananda‐Rajah, Michelle R. Kidd, Sarah E. Williams, Eloise Chee, Lynette Urbancic, Karen Thursky, Karin A. |
description | Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug–drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted. |
doi_str_mv | 10.1111/imj.15586 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2613289984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2613289984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3886-b22ca8715cccf7b86ce009f474a001e126d9c71038cb9e5e33e5fd8f034fced43</originalsourceid><addsrcrecordid>eNp10M1LwzAYBvAgipvTg_-AFLworFu-2iZHGX5MJl70JpQ2fTMz2nQm68b-e9ttehDMJe_hx8PDg9AlwSPSvrGpFiMSRSI-Qn3CeRRGUvLj3c1DLDHroTPvFxiThEl-inqMS5YQxvvoY1JbD9Y3Ppg3poDSWPCBrl2Q2ZXRjZ1nZeBXsMlc4T_Nchj4xq3BlGVmFbSoCIzVoFamtsHSwRpsdw4Diik5Ryc6Kz1cHP4Ben-4f5s8hbPXx-nkbhYqJkQc5pSqTCQkUkrpJBexAoyl5gnP2spAaFxIlRDMhMolRMAYRLoQGjOuFRScDdDNPnfp6q8G_CqtjFfQdYS68SmNCaNCStHR6z90UTfOtu06RXmMZUJbdbtXytXeO9Dp0pkqc9uU4LSbPG0nT3eTt_bqkNjkFRS_8mfjFoz3YGNK2P6flE5fnveR3yC7iu4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2612460972</pqid></control><display><type>article</type><title>Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Khanina, Anna ; Tio, Shio Yen ; Ananda‐Rajah, Michelle R. ; Kidd, Sarah E. ; Williams, Eloise ; Chee, Lynette ; Urbancic, Karen ; Thursky, Karin A.</creator><creatorcontrib>Khanina, Anna ; Tio, Shio Yen ; Ananda‐Rajah, Michelle R. ; Kidd, Sarah E. ; Williams, Eloise ; Chee, Lynette ; Urbancic, Karen ; Thursky, Karin A. ; Australasian Antifungal Guidelines Steering Committee ; Australasian Antifungal Guidelines Steering Committee</creatorcontrib><description>Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug–drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted.</description><identifier>ISSN: 1444-0903</identifier><identifier>EISSN: 1445-5994</identifier><identifier>DOI: 10.1111/imj.15586</identifier><identifier>PMID: 34937134</identifier><language>eng</language><publisher>Melbourne: John Wiley & Sons Australia, Ltd</publisher><subject>Antifungal agents ; Antifungal Agents - therapeutic use ; antifungal stewardship ; Candidiasis, Invasive - drug therapy ; Candidiasis, Invasive - epidemiology ; Candidiasis, Invasive - prevention & control ; Consensus ; Drug Resistance, Fungal ; hospital building work ; Hospitals ; Humans ; Immunocompromised Host ; Immunocompromised hosts ; infection prevention ; Infections ; invasive fungal disease ; Invasiveness ; outbreak management ; Outbreaks ; Prevention ; Prophylaxis ; quality process ; Surveillance</subject><ispartof>Internal medicine journal, 2021-11, Vol.51 (S7), p.18-36</ispartof><rights>2021 Royal Australasian College of Physicians.</rights><rights>2021 Royal Australasian College of Physicians</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3886-b22ca8715cccf7b86ce009f474a001e126d9c71038cb9e5e33e5fd8f034fced43</citedby><cites>FETCH-LOGICAL-c3886-b22ca8715cccf7b86ce009f474a001e126d9c71038cb9e5e33e5fd8f034fced43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fimj.15586$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fimj.15586$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34937134$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khanina, Anna</creatorcontrib><creatorcontrib>Tio, Shio Yen</creatorcontrib><creatorcontrib>Ananda‐Rajah, Michelle R.</creatorcontrib><creatorcontrib>Kidd, Sarah E.</creatorcontrib><creatorcontrib>Williams, Eloise</creatorcontrib><creatorcontrib>Chee, Lynette</creatorcontrib><creatorcontrib>Urbancic, Karen</creatorcontrib><creatorcontrib>Thursky, Karin A.</creatorcontrib><creatorcontrib>Australasian Antifungal Guidelines Steering Committee</creatorcontrib><creatorcontrib>Australasian Antifungal Guidelines Steering Committee</creatorcontrib><title>Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021</title><title>Internal medicine journal</title><addtitle>Intern Med J</addtitle><description>Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug–drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted.</description><subject>Antifungal agents</subject><subject>Antifungal Agents - therapeutic use</subject><subject>antifungal stewardship</subject><subject>Candidiasis, Invasive - drug therapy</subject><subject>Candidiasis, Invasive - epidemiology</subject><subject>Candidiasis, Invasive - prevention & control</subject><subject>Consensus</subject><subject>Drug Resistance, Fungal</subject><subject>hospital building work</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Immunocompromised hosts</subject><subject>infection prevention</subject><subject>Infections</subject><subject>invasive fungal disease</subject><subject>Invasiveness</subject><subject>outbreak management</subject><subject>Outbreaks</subject><subject>Prevention</subject><subject>Prophylaxis</subject><subject>quality process</subject><subject>Surveillance</subject><issn>1444-0903</issn><issn>1445-5994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10M1LwzAYBvAgipvTg_-AFLworFu-2iZHGX5MJl70JpQ2fTMz2nQm68b-e9ttehDMJe_hx8PDg9AlwSPSvrGpFiMSRSI-Qn3CeRRGUvLj3c1DLDHroTPvFxiThEl-inqMS5YQxvvoY1JbD9Y3Ppg3poDSWPCBrl2Q2ZXRjZ1nZeBXsMlc4T_Nchj4xq3BlGVmFbSoCIzVoFamtsHSwRpsdw4Diik5Ryc6Kz1cHP4Ben-4f5s8hbPXx-nkbhYqJkQc5pSqTCQkUkrpJBexAoyl5gnP2spAaFxIlRDMhMolRMAYRLoQGjOuFRScDdDNPnfp6q8G_CqtjFfQdYS68SmNCaNCStHR6z90UTfOtu06RXmMZUJbdbtXytXeO9Dp0pkqc9uU4LSbPG0nT3eTt_bqkNjkFRS_8mfjFoz3YGNK2P6flE5fnveR3yC7iu4</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Khanina, Anna</creator><creator>Tio, Shio Yen</creator><creator>Ananda‐Rajah, Michelle R.</creator><creator>Kidd, Sarah E.</creator><creator>Williams, Eloise</creator><creator>Chee, Lynette</creator><creator>Urbancic, Karen</creator><creator>Thursky, Karin A.</creator><general>John Wiley & Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202111</creationdate><title>Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021</title><author>Khanina, Anna ; Tio, Shio Yen ; Ananda‐Rajah, Michelle R. ; Kidd, Sarah E. ; Williams, Eloise ; Chee, Lynette ; Urbancic, Karen ; Thursky, Karin A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3886-b22ca8715cccf7b86ce009f474a001e126d9c71038cb9e5e33e5fd8f034fced43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antifungal agents</topic><topic>Antifungal Agents - therapeutic use</topic><topic>antifungal stewardship</topic><topic>Candidiasis, Invasive - drug therapy</topic><topic>Candidiasis, Invasive - epidemiology</topic><topic>Candidiasis, Invasive - prevention & control</topic><topic>Consensus</topic><topic>Drug Resistance, Fungal</topic><topic>hospital building work</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Immunocompromised hosts</topic><topic>infection prevention</topic><topic>Infections</topic><topic>invasive fungal disease</topic><topic>Invasiveness</topic><topic>outbreak management</topic><topic>Outbreaks</topic><topic>Prevention</topic><topic>Prophylaxis</topic><topic>quality process</topic><topic>Surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khanina, Anna</creatorcontrib><creatorcontrib>Tio, Shio Yen</creatorcontrib><creatorcontrib>Ananda‐Rajah, Michelle R.</creatorcontrib><creatorcontrib>Kidd, Sarah E.</creatorcontrib><creatorcontrib>Williams, Eloise</creatorcontrib><creatorcontrib>Chee, Lynette</creatorcontrib><creatorcontrib>Urbancic, Karen</creatorcontrib><creatorcontrib>Thursky, Karin A.</creatorcontrib><creatorcontrib>Australasian Antifungal Guidelines Steering Committee</creatorcontrib><creatorcontrib>Australasian Antifungal Guidelines Steering Committee</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Internal medicine journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khanina, Anna</au><au>Tio, Shio Yen</au><au>Ananda‐Rajah, Michelle R.</au><au>Kidd, Sarah E.</au><au>Williams, Eloise</au><au>Chee, Lynette</au><au>Urbancic, Karen</au><au>Thursky, Karin A.</au><aucorp>Australasian Antifungal Guidelines Steering Committee</aucorp><aucorp>Australasian Antifungal Guidelines Steering Committee</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021</atitle><jtitle>Internal medicine journal</jtitle><addtitle>Intern Med J</addtitle><date>2021-11</date><risdate>2021</risdate><volume>51</volume><issue>S7</issue><spage>18</spage><epage>36</epage><pages>18-36</pages><issn>1444-0903</issn><eissn>1445-5994</eissn><abstract>Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug–drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted.</abstract><cop>Melbourne</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>34937134</pmid><doi>10.1111/imj.15586</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1444-0903 |
ispartof | Internal medicine journal, 2021-11, Vol.51 (S7), p.18-36 |
issn | 1444-0903 1445-5994 |
language | eng |
recordid | cdi_proquest_miscellaneous_2613289984 |
source | MEDLINE; Wiley Journals |
subjects | Antifungal agents Antifungal Agents - therapeutic use antifungal stewardship Candidiasis, Invasive - drug therapy Candidiasis, Invasive - epidemiology Candidiasis, Invasive - prevention & control Consensus Drug Resistance, Fungal hospital building work Hospitals Humans Immunocompromised Host Immunocompromised hosts infection prevention Infections invasive fungal disease Invasiveness outbreak management Outbreaks Prevention Prophylaxis quality process Surveillance |
title | Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T02%3A42%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Consensus%20guidelines%20for%20antifungal%20stewardship,%20surveillance%20and%20infection%20prevention,%202021&rft.jtitle=Internal%20medicine%20journal&rft.au=Khanina,%20Anna&rft.aucorp=Australasian%20Antifungal%20Guidelines%20Steering%20Committee&rft.date=2021-11&rft.volume=51&rft.issue=S7&rft.spage=18&rft.epage=36&rft.pages=18-36&rft.issn=1444-0903&rft.eissn=1445-5994&rft_id=info:doi/10.1111/imj.15586&rft_dat=%3Cproquest_cross%3E2613289984%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2612460972&rft_id=info:pmid/34937134&rfr_iscdi=true |